Researchers from Siriraj Hospital, Mahidol University in Thailand have successfully used a closed, semi-automated production platform to produce anti-CD19 CAR-T cells for the treatment of relapsed/refractory B-cell malignancies. This point-of-care (POC) manufacturing approach allows for the production of CAR-T cells at the treatment site, which reduces the cost and complexity of the manufacturing process. The researchers found that this POC manufacturing approach is feasible and can produce CAR-T cells that meet the same quality and safety standards as those produced using traditional methods. This is good news for patients in Thailand and other developing countries, as it could make CAR-T cell therapy more accessible and affordable.
Funding
This study was supported by the Siriraj Foundation (D707070 and D003276).
Original Paper
Title of original paper: Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand
Journal: Molecular Therapy Oncology
DOI: 10.1016/j.omton.2024.200889
Correspondence
Sudjit Luanpitpong (email: [email protected])and Surapol Issaragrisil (email: [email protected])